Although PARP inhibitors like olaparib and talazoparib enhance radiation responses, studies suggest that lung adenocarcinoma cells may recover proliferative ability, raising the risk of recurrence [18]. This evidence concerns the gene PARP1 and lung adenocarcinoma.